- · 《产业创新研究》收稿方[05/28]
- · 《产业创新研究》投稿方[05/28]
- · 《产业创新研究》征稿要[05/28]
- · 《产业创新研究》刊物宗[05/28]
科学社会与市场视角下的精准医学创新(6)
作者:网站采编关键词:
摘要:[1]Brian S,Zhou Y,Saheli and the Politics of Innovation in the Life Sciences:Science and the State in the United Kingdom,China and India[J].Science TechnologyTechnology Studies,2017(3).
[1]Brian S,Zhou Y,Saheli and the Politics of Innovation in the Life Sciences:Science and the State in the United Kingdom,China and India[J].Science Technology&Human Values,2016(5).
[2]Sankar,P. L.,Parker,L. S. The Precision Medicine Initiative’s All of Us Research Program:an Agenda for Research on Its Ethical,Legal and Social Issues[J].Genetics in Medicine,2016(19).
[3] 詹启敏. 中国精准医学发展的战略需求和重点任务[J]. 中华神经创伤外科电子杂志,2015(5).
[4]Hooghe,L.,G Marks. Unravelling the Central State,but How?Types of Multi-level Governance[J]. A Merican Political Science Review,2003(2).
[5]Laredo P,Mustar Conclusion:Three Major Trends in Research and Innovation Policies[A].Laredo P.,Mustar P.,eds. Research and Innovation Policies in the New Global Economy:an International Comparative Perspective[C]. Cheltenham:Edward Elgar,2001.
[6]Asheim,B. T.,Gertler,M. S. The Geography of Innovation:Regional Innovation Systems[A]. Fagerberg,J.,Mowery,D. Nelson,R.,eds.The Oxford Handbook of Innovation[C].Oxford:Oxford University Press,2004.
[7]Cooke, Knowledge Capabilities,Embeddedness of Firms and Industry Organisation:Bioscience Megacentres and Economic Geography[J].European Planning Studies,2004(7).
[8]Salter,B. Governing Innovation Paths in Regenerative Medicine:The European and Global Struggle for Political Advantage[M].London:Palgrave Macmillan,2013.
[9]Ladikas,M.,Chaturvedi,S.,Zhao,, and Technology Governance and Ethics[M].Berlin:Springer International Publishing,2015.
[10]Salter,,A.State Strategies of Governance in Biomedical Innovation:Aligning Conceptual Approaches for Understanding“Rising Powers”in the Global Context[J].Globalization and Health,2011(1).
[11]Salter,B.,Salter,C. Governing Innovation in the Biomedicine Knowledge Economy:Stem Cell Science in the USA[J]. Science and Public Policy,2010(2).
[12]张来武. 科技创新的宏观管理:从公共管理走向公共治理[J]. 中国软科学,2012(6).
[13]陈套,冯锋,尤超良. 治理语境下创新主体决策参与和路径建构[J]. 科学管理研究,2016(1).
[14]赵延东,廖苗. 负责任研究与创新在中国[J]. 中国软科学,2017(3).
[15]Harvey,M., or Private Economies of Knowledge:The Economics of Diffusion and Appropriation of Bioinformatics Tools[J].International Journal of the Commons,2010(1).
[16]Faulkner A. Bioinformatics Imaginaries in the Engine-room of Genomic Health Policy[J]. Science&Technology Studies,2017(3).
[17]赵爱民. 生物信息技术发展态势分析[J]. 中国生物工程杂志,2003(5).
[18]艾瑞婷,王德平.“十一五”863计划“生物信息和生物计算技术”专题课题布局及实施情况分析[J]. 中国生物工程杂志,2011(12).
[19]Prasad :The Precision-oncology Illusion[J].Nature,2016(537).
[20]Tannock I F,Hickman J A.Limits to Personalized Cancer Medicine[J].New England Journal of Medicine,2016(375).
[21]冯俊华. 企业管理概论[M]. 北京:化学工业出版社,2011.
[22]Gupta N,Fischer A R H,Frewer L Determinants of Public Acceptance of Technologies:A Review[J].Public Understanding of Sciences,2011(7).
[23]邱仁宗,翟晓梅. 精准医学:对伦理和管理的挑战[J]. 中国医学伦理学,2017(4).
[24]Callier S L,Abudu R,Mehlman M J,et al. Ethical,Legal,and Social Implications of Personalized Genomic Medicine Research:Current Literature and Suggestions for the Future[J].Bioethics,2016(9).
[25]Salter B,Zhou Y,Datta S. Governing New Global Health-care Markets:The Case of Stem Cell Treatments[J]. New Political Economy,2017(1).
[26]周殷华,程瑜. 国际干细胞医疗市场治理与医生的职业价值观[J]. 广西民族大学学报(哲学社会科学版),2017(1).
[27]Barker,R. W.,Scannell,J. W. The Life Sciences Translational Challenges:The European Perspective[J]. Therapeutic Innovation&Regulatory Science,2015(3).
文章来源:《产业创新研究》 网址: http://www.cycxyj.cn/qikandaodu/2021/0709/1781.html